KR20160003634A - 고도로 갈락토실화된 항-her2 항체 및 이의 용도 - Google Patents

고도로 갈락토실화된 항-her2 항체 및 이의 용도 Download PDF

Info

Publication number
KR20160003634A
KR20160003634A KR1020157024975A KR20157024975A KR20160003634A KR 20160003634 A KR20160003634 A KR 20160003634A KR 1020157024975 A KR1020157024975 A KR 1020157024975A KR 20157024975 A KR20157024975 A KR 20157024975A KR 20160003634 A KR20160003634 A KR 20160003634A
Authority
KR
South Korea
Prior art keywords
antibody
antibodies
population
epithelial cells
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157024975A
Other languages
English (en)
Korean (ko)
Inventor
해리 엠. 미드
리하우 첸
Original Assignee
라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 filed Critical 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스
Publication of KR20160003634A publication Critical patent/KR20160003634A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
KR1020157024975A 2013-02-13 2014-02-13 고도로 갈락토실화된 항-her2 항체 및 이의 용도 Withdrawn KR20160003634A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764488P 2013-02-13 2013-02-13
US61/764,488 2013-02-13
PCT/IB2014/000711 WO2014125377A2 (en) 2013-02-13 2014-02-13 Highly galactosylated anti-her2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20160003634A true KR20160003634A (ko) 2016-01-11

Family

ID=50980322

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024975A Withdrawn KR20160003634A (ko) 2013-02-13 2014-02-13 고도로 갈락토실화된 항-her2 항체 및 이의 용도

Country Status (13)

Country Link
US (1) US20150368357A1 (cg-RX-API-DMAC7.html)
EP (1) EP2956485A2 (cg-RX-API-DMAC7.html)
JP (2) JP2016509019A (cg-RX-API-DMAC7.html)
KR (1) KR20160003634A (cg-RX-API-DMAC7.html)
CN (1) CN105308071A (cg-RX-API-DMAC7.html)
AR (1) AR094781A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014217564B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015019343A2 (cg-RX-API-DMAC7.html)
CA (1) CA2900912A1 (cg-RX-API-DMAC7.html)
IL (1) IL240440A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015010428A (cg-RX-API-DMAC7.html)
TW (1) TW201444870A (cg-RX-API-DMAC7.html)
WO (1) WO2014125377A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429272A (zh) 2010-12-30 2013-12-04 法国化学与生物科技实验室 作为病原体灭活剂的二元醇
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
CN105263319A (zh) 2013-02-13 2016-01-20 法国化学与生物科技实验室 具有经修饰的糖基化的蛋白及其生产方法
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
WO2016037947A1 (en) * 2014-09-10 2016-03-17 F. Hoffmann-La Roche Ag Galactoengineered immunoglobulin 1 antibodies
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
MA52783A (fr) * 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
CN112566667B (zh) * 2018-06-15 2023-06-09 上海美雅珂生物技术有限责任公司 治疗癌症的方法和材料
WO2022022526A1 (zh) * 2020-07-28 2022-02-03 百奥泰生物制药股份有限公司 抗her2抗体及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
ES2434961T5 (es) * 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
ES2561985T3 (es) * 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CN101484470B (zh) * 2005-10-21 2014-07-23 阿伊沃生物制剂有限公司 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
CA2655246A1 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
LT2511301T (lt) * 2006-08-04 2018-04-10 Medimmune Limited Žmogaus antikūnas prieš erbb2
ZA200901912B (en) * 2006-09-10 2010-06-30 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
KR101603632B1 (ko) * 2006-09-10 2016-03-16 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
CA2734139C (en) * 2007-10-02 2019-12-24 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US8084222B2 (en) * 2008-09-26 2011-12-27 Eureka Therapeutics, Inc. Methods for generating host cells
JPWO2012105699A1 (ja) * 2011-02-03 2014-07-03 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
US8809017B2 (en) * 2011-05-24 2014-08-19 Agency For Science, Technology And Research IRES mediated multicistronic vectors
KR20160002713A (ko) * 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도

Also Published As

Publication number Publication date
TW201444870A (zh) 2014-12-01
MX2015010428A (es) 2016-04-13
WO2014125377A2 (en) 2014-08-21
CN105308071A (zh) 2016-02-03
WO2014125377A3 (en) 2014-12-04
AU2014217564B2 (en) 2018-11-08
JP2020125286A (ja) 2020-08-20
IL240440A0 (en) 2015-09-24
JP2016509019A (ja) 2016-03-24
US20150368357A1 (en) 2015-12-24
EP2956485A2 (en) 2015-12-23
CA2900912A1 (en) 2014-08-21
BR112015019343A2 (pt) 2017-08-22
AR094781A1 (es) 2015-08-26
AU2014217564A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
EP2741769B1 (en) Highly galactosylated antibodies
KR20160003634A (ko) 고도로 갈락토실화된 항-her2 항체 및 이의 용도
US20200255518A1 (en) Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
JP2020073550A (ja) 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用
AU2012293420B2 (en) Highly galactosylated antibodies
AU2012201010B2 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
AU2015201981A1 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150911

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid